Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T18:48:16.626Z.
Calculation as of: 2026-10-06T18:48:16.626Z.
Quote observation: 2026-10-06T18:45:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae890bbb10947f62e3ed18d2c50ad40899bde2d85958fa14f481db4a948b3095
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $248.70M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $246.48M | N/A | N/A | N/A | N/A |
| Quantum-Si incorporated (QSI)vs › | $246.29M | N/A | N/A | N/A | N/A |
| Century Therapeutics, Inc. (IPSC)vs › | $245.36M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $242.87M | N/A | N/A | N/A | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 2.31 | 2.31 | 2.31 |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.54M | N/A | 1.36 | 0.90 | 0.77 |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $238.81M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $258.50M | N/A | 0.41 | 0.41 | 0.41 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
